The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinase, on a new animal model of epiretinal membrane

Retina

Volumn 24, Issue 5, 2004, Pages 783-789

  El Bradey, Mohamed H ^a   Cheng, Lingyun ^a   Bartsch, Dirk Uwe ^a   Niessman, Michael ^b   El Musharaf, Abbas ^a   Freeman, William R ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AGOURON PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Animal model; Epiretinal membrane; Laser coagulation; Metalloproteinase

Indexed keywords

COLLAGEN; HYALURONIC ACID; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURN; CHOROID VASCULARIZATION; CONTROLLED STUDY; DIODE LASER; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; EPIRETINAL MEMBRANE; EXTRACELLULAR MATRIX; FIBROBLAST; GLIA CELL; IMMUNOHISTOCHEMISTRY; LASER BURN; LASER COAGULATION; MACROPHAGE; NONHUMAN; RAT; RAT STRAIN; RETINA HEMORRHAGE;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EPIRETINAL MEMBRANE; FEMALE; INJECTIONS; LASER COAGULATION; MATRIX METALLOPROTEINASES; ORGANIC CHEMICALS; RATS; RATS, INBRED BN; RETINAL HEMORRHAGE; VITREOUS BODY;

EID: 6344225957     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200410000-00016     Document Type: Article

References (26)

1. Winthrop SR, Cleary PE, Minckler DS, Ryan SJ. Penetrating eye injuries: a histological review. Br J Ophthalmol 1980;64: 809-817.
2. Cibis P. Vitreoretinal pathology and surgery in retinal detachment. St Louis: Mosby-Year Book, 1965.
3. Hogan MJ. Inflammation and its effect on the vitreous. Trans Ophthalmol Soc UK 1975;95:378-381.
4. Roth AM, Foos RY. Surface wrinkling retinopathy in eyes enucleated at autopsy. Trans Am Acad Ophthalmol Otolaryngol 1971;75:1047-1058.
5. Matsumoto B, Hsu HT, Blanks JC, Ryan SJ. Morphological study of epiretinal membrane following posterior penetrating injury in the monkey eye. Curr Eye Res 1986;5:295-305.
6. Kono T, Kohno T, Inomata H. Epiretinal membrane formation: light and electron microscopic study in an experimental rabbit model. Arch Ophthalmol 1995;113:359-363.
7. Hui YN, Sorgente N, Ryan SJ. Ultrastructures of the glial epiretinal membrane induced by activated macrophages. Chin Med J (Engl) 1992;105:577-581.
8. Gilbert C, Hiscott P, Unger W, et al. Inflammation and the formation of epiretinal membranes. Eye 1988;2(Suppl): S140-S156.
9. Limb GA, Alam A, Earley O, et al. Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr Eye Res 1994;13:791-798.
10. Scheiffarth OF, Kampik A, Gunther H, von der Mark K. Proteins of the extracellular matrix in vitreoretinal membranes. Graefes Arch Clin Exp Ophthalmol 1988;226:357-361.
11. Salzmann J, Limb GA, Khaw PT, et al. Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 2000:84:1091-1096.
12. Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999;878:236-270.
13. Zhang KE, McDermott CK, Brekken J. Ocular bioavailability and pharmacokinetics of AG3340, a potent MMP inhibitor with anti angiogenic activity, following oral administration. Proc N Y Acad Sci Tampa, FL, 1998.
14. Oguchi C. Uber die Wrinkung von Blutinjektionen in den Glaskorper nebst Bemerkungen uber die Sog: Retinitis proliferation. Graefes Arch Clin Exp Ophthalmol 1913;84:446-520.
15. Ehrenberg M, Thresher RJ, Machemer R. Vitreous hemorrhage nontoxic to retina as a stimulator of glial and fibrous proliferation. Am J Ophthalmol 1984;97:611-626.
16. Lean JS. Origin of simple glial epiretinal membranes in an animal model. Graefes Arch Clin Exp Ophthalmol 1987;225: 421-425.
17. Gonzalez-Avila G, Lozano D, Manjarrez ME, et al. Influence on collagen metabolism of vitreous from eyes with proliferative vitreoretinopathy. Ophthalmology 1995;102:1400-1405.
18. Webster L, Chignell AH, Limb GA. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy. Exp Eye Res 1999;68:91-98.
19. Ozerdem U, Mach-Hofacre B, Cheng L, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res 2000;20:447-453.
20. Ozerdem U, Mach-Hofacre B, Keefe K, et al. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res 2001:33:20-23.
21. Ryan SJ. Traction retinal detachment. XLIX Edward Jackson Memorial Lecture. Am J Ophthalmol 1993;115:1-20.
22. Ozerdem U, Mach-Hofacre B, Varki N, Folberg R, Mueller AJ, Ochabski R, et al. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model. Curr Eye Res 2002:24;86-91.
23. Garcia RC, Rivero ME, Hagedorn M, McDermott C, Bergeron-Lynn G, Appelt K, Freeman WR. Efficacy of prinomastat (AG3340), a matrix metalloproteinase inhibitor in treatment of retinal neovascularization. Curr Eye Res 2002; 24:33-38.
24. Deryugina EI, Ratnikov BI, Strongin AY. Prinomastat, a hydroxamate inhibitor of matrix metalloproteinases, has a complex effect on migration of breast carcinoma cells. Int J Cancer 2003;104:533-541.
25. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002;29(1 Suppl 4):78-86.
26. Cheng L, Rivero ME, Garcia CR, et al. Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J Ocul Pharmacol Ther 2001;17:295-304.